Allergic Bronchopulmonary Aspergillosis With Elevated CEA Is Infrequent

2. Ojanguren I, Morell F, Ramón MA, Villar A, Romero C, Cruz MJ, et al. Long-term outcomes in chronic hypersensitivity pneumonitis. Allergy. 2019;74:944–52. 3. De Sadeleer LJ, Hermans F, De Dycker E, Yserbyt J, Verschakelen JA, Verbeken EK, et al. Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort: a single-centre cohort study. J Clin Med. 2018;8:14. 4. Jordan S, Distler JHW, Maurer B, Huscher D, van Laar JM, Allanore Y, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74:1188–94. 5. Mohammed AGA, Alshihre A, Al-Homood IA. Rituximab treatment in patients with systemic sclerosis and interstitial lung disease. Ann Thorac Med. 2017;12:294–7. 6. Lota HK, Keir GJ, Hansell DM, Nicholson AG, Maher TM, Wells AU, et al. Novel use of rituximab in hypersensitivity pneumonitis refractory to conventional treatment. Thorax. 2013;68:780–1. 7. Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014;19:353–9. 8. Schuyler M, Cormier Y. The diagnosis of hypersensitivity pneumonitis. Chest. 1997;111:534–6. 9. Vasakova M, Morell F, Walsh S, Leslie K, Raghu G. Hypersensitivity pneumonitis: perspectives in diagnosis and management. Am J Respir Crit Care Med. 2017;196:680–9. 10. du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, et al. 6Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2014;43:1421–9. 11. Barrera L, Mendoza F, Zuñiga J, Estrada A, Zamora AC, Melendro EI, et al. Functional diversity of T-cell subpopulations in subacute and chronic hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2008;177:44–55.